Sepsis is the most common cause of morbidity and mortality in ICU patients. The clinical signs of infection and routine laboratory tests are not specific and at times misleading. Even the bacteriological evidence of infection is not sensitive enough. In view of this diagnostic and therapeutic dilemma, an effective and specific marker is needed that can support or exclude the diagnosis of infection. Hence we evaluated the usefulness of biochemical markers such as procalcitonin (PCT) and high-sensitivity C reactive protein (hsCRP) in monitoring the therapeutic response to treatment in patients with sepsis.